
Simulations Plus (SLP) Stock Forecast & Price Target
Simulations Plus (SLP) Analyst Ratings
Bulls say
Simulations Plus Inc. reported total revenue of $20.4 million for the third fiscal quarter, aligning with consensus expectations and slightly exceeding its guidance range, indicating strong financial performance stability. The company's recent Proficiency acquisition presents opportunities for organic revenue growth to potentially re-accelerate toward high-single digits in fiscal year 2026, despite challenges stemming from customer concentration in the biotech sector. Additionally, the company maintains a healthy revenue mix, with expectations of 55-60% coming from software and 40-45% from services, underscoring its solid foundation in the pharmaceutical software industry.
Bears say
Simulations Plus, Inc. faces significant challenges due to its high customer concentration and exposure to the struggling biotech sector, which is anticipated to continue affecting demand negatively in the near to mid-term. The recent financial performance revealed that its software revenue of $12.6 million fell short of the consensus estimate of $13.6 million, indicating potential weaknesses in its main revenue-generating segment. Despite a modestly positive adjusted EBITDA of $7.4 million, the higher-than-expected SG&A expense and lower R&D expenditure compared to consensus further highlight concerns regarding the company's financial management and strategic positioning in a challenging market environment.
This aggregate rating is based on analysts' research of Simulations Plus and is not a guaranteed prediction by Public.com or investment advice.
Simulations Plus (SLP) Analyst Forecast & Price Prediction
Start investing in Simulations Plus (SLP)
Order type
Buy in
Order amount
Est. shares
0 shares